EuropaBio Principles for Genetic Testing and Testing for Genetically Driven Risk Factors
Advances in science and technology have greatly improved our understanding of the genetic basis of disease, which have made it possible to redefine many diseases at higher resolution and target them with more precise treatments such as cell and gene therapies.
Increased access to genetic testing is a significant opportunity for patients and healthcare systems in Europe by supporting the deployment of targeted therapeutic strategies. With knowledge, people at risk of developing diseases may take steps towards prevention. New therapies can transform lives if they reach the right patients at the right time. Whether for screening, early or confirmatory diagnosis, or patient stratification, genetic testing can support medical decision-making, empowering patients and helping healthcare systems use the most appropriate treatments.
To support the uptake of genetic testing, EuropaBio propose a set of 12 policy principles and associated recommendations across the following areas:
EuropaBio invite policy-makers and other relevant stakeholders to engage with us on this topic and unlock the path of innovation for next generation medicines to the benefit of European patients, healthcare systems, and society.
Click on the button below to read the full report.